articleObstetrical & Gynecological SurveyFeb 23, 2009Closed access

Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein

Brigham and Women's Hospital · St. Luke's Episcopal Hospital · +11 more institutions

Indexed incrossref

Abstract

Previous studies have shown that statin therapy reduces high-sensitivity C-reactive protein levels as well as cholesterol, but no prospective trials have directly addressed the issue of whether elevated levels of high-sensitivity C-reactive protein are beneficial for apparently healthy persons with levels of LDL cholesterol below current thresholds for treatment. This randomized, double-blind, placebo-controlled, multicenter trial study was part of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) Study. The present study evaluated the effects of rosuvastatin, 20 mg daily, or placebo in 17,802 apparently healthy men and women with LDL cholesterol…

Citation impact

3,658
total citations
FWCI
425.91
Percentile
100%
References
0
Citations per year

Authors

14

Topics & keywords

Keywords
  • Rosuvastatin
  • Medicine
  • Placebo
  • Hazard ratio
  • C-reactive protein
  • Rosuvastatin Calcium
  • Internal medicine
  • Confidence interval
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.